Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Gemcitabine,GemStudy001,2021,USA,MDV,350,68,45,55,26.5,62,78,12,15,30,40,15,45,30,15,10,20,35,45,18,8,5,10,7,35,48,55,Gemcitabine + Cisplatin,Gemcitabine + Paclitaxel,Gemcitabine,Gemcitabine + Capecitabine,0,0,0,25,65,50,15,45,40,60,2
Gemcitabine,PanCan2022,2022,Germany,Claim Database,420,72,52,48,27.1,58,72,8,12,28,42,18,40,32,18,10,18,32,50,22,10,6,12,9,30,45,50,Gemcitabine + Carboplatin,Gemcitabine + Docetaxel,Gemcitabine,5-FU,0,0,0,28,68,55,12,48,40,65,1.5
Gemcitabine,AsiaOnco23,2023,Japan,MDV,280,65,48,52,24.8,45,85,5,20,35,35,10,50,28,12,10,25,40,35,15,6,4,8,5,40,52,60,Gemcitabine + S-1,Gemcitabine,Gemcitabine,S-1,0,0,0,22,62,48,18,52,30,70,2.5
